SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is capturing attention as community members rally behind its organic growth strategy, actively avoiding the typical pump-and-dump cycles associated with other meme tokens. Investors are showing strong conviction in the project's long-term potential, frequently discussing its lack of a chart as a badge of early-stage authenticity while pushing for increased volume to drive the next leg of upward momentum.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as the community leans into its history as an original internet parody, positioning it as a cultural counter-narrative to traditional crypto assets. Discussions are dominated by debates over its long-term viability, with vocal supporters framing it as a multi-billion dollar opportunity while others dismiss the project as part of a wider trend of memetic absurdity.

ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. Its product portfolio includes IV smart pumps, sets, connectors, closed system transfer devices for hazardous drugs, sterile IV solutions, cardiac monitoring systems, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.

ICU Medical, Inc.

ICU Medical is trending as investors evaluate its integration of recent acquisitions and the company's long-term growth potential in the infusion systems and medical device market. The community remains focused on technical turnaround potential, management performance, and the company's ability to drive hospital adoption for its specialized device products.

DaVita, Inc. engages in the provision of medical care services. It operates through the US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offer kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consists primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita is seeing significant trading activity as investors react to concerns over the impact of GLP-1 weight-loss drugs on the long-term demand for dialysis services. While the market has reacted sharply to clinical trial news from the obesity drug sector, analysts and community participants are actively debating whether this sell-off represents an overreaction or a fundamental shift in the kidney care landscape.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is generating significant community buzz as investors debate its long-term transactional utility against Bitcoin, with many keeping a close watch on potential catalysts like institutional adoption and integration with major platforms. Traders are currently split between viewing the asset as a prime short-squeeze opportunity and maintaining a cautious stance amidst broader market volatility.

Vanguard World Fund - Vanguard Emerging Markets Ex-China ETF

Investors are increasingly utilizing this ETF as a strategic alternative to gain exposure to emerging markets while intentionally avoiding Chinese equities. Market participants are actively debating the merits of geographical diversification in response to heightened geopolitical volatility and concerns regarding systemic stability in international markets.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is currently trending as investors debate the potential for a renewed upward leg, with many pointing to the recent Canary Capital ETF filing as a major catalyst for institutional legitimacy. The community remains divided between those viewing the current volatility as a prime accumulation zone and others cautioning against meme coin cyclicality, while overall sentiment remains heavily tethered to broader Bitcoin and Ethereum market trends.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is experiencing heightened volatility and intense social debate, with bulls pointing to potential legislative catalysts like the Clarity Act and accumulation trends, while bears express deep skepticism, citing long-term price underperformance and dismissing the project as a cycle-dependent scam.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is facing increased volatility and investor scrutiny as shareholders navigate the impact of conservative forward revenue guidance and the upcoming transition in reimbursement for DefenCath. While the community remains divided over management's communication and strategy, discussion is heavily focused on potential legislative catalysts like the Kidney Care Access Protection Act and the anticipated readout of Phase 3 trial data for Rezzayo.

ARK 21Shares Bitcoin ETF - ARK 21Shares Bitcoin ETF Beneficial Interest

ARK 21Shares Bitcoin ETF

Investors are closely monitoring Bitcoin ETFs like ARKB, IBIT, and FBTC as sustained institutional demand and significant daily inflows continue to drive market sentiment despite recent price volatility. The broader community remains focused on the potential impact of the upcoming halving and the long-term role of Bitcoin as a strategic asset amidst ongoing macroeconomic shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Edesa Biotech (NASDAQ:EDSA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Edesa Biotech from a "sell" rating to a "hold" rating in a research note on Sunday...

Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 9,253.7%

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) saw a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 1,411,103 shares...

Best Biotech Stocks To Follow Today - March 7th

Danaher, Moderna, Vertex Pharmaceuticals, argenex, Iovance Biotherapeutics, Edesa Biotech, and ImmunityBio are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Pardeep Nijhawan Purchases 10,000 Shares of Edesa Biotech (NASDAQ:EDSA) Stock

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan purchased 10,000 shares of Edesa Biotech stock in a transaction dated Thursday, March 5th. The shares were purchased at an...

Edesa Biotech (NASDAQ:EDSA) CEO Pardeep Nijhawan Acquires 10,000 Shares

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan purchased 10,000 shares of the firm's stock in a transaction on Thursday, March 5th. The shares were acquired at an average...

Edesa Biotech (NASDAQ:EDSA) CEO Buys $36,300.00 in Stock

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan acquired 10,000 shares of the business's stock in a transaction dated Tuesday, March 3rd. The stock was acquired at an average...

Pardeep Nijhawan Acquires 30,000 Shares of Edesa Biotech (NASDAQ:EDSA) Stock

Edesa Biotech, Inc. (NASDAQ:EDSA - Get Free Report) CEO Pardeep Nijhawan purchased 30,000 shares of the business's stock in a transaction on Friday, February 27th. The shares were purchased at an...

<ul class="summary-bullets"><li>The company on Tuesday reported results from a 278-patient population, including 104 patients requiring invasive mechanical ventilation (IMV) as well as 174 non-IMV patients.</li><li>Overall rates of adverse events, serious adverse events, infections and treatment discontinuations were low and similar between the paridiprubart and placebo groups, the company said.&nbsp;</li><li>The company is advancing regulatory discussions and evaluating strategic collaborations and partnership opportunities, the CEO said.</li></ul>Shares of Edesa Biotech, Inc. jumped 76% on Tuesday after the company announced that data from a late-stage study of its experimental drug for the treatment of Acute Respiratory Distress Syndrome affirmed statistically significant mortality reductions.Acute respiratory distress syndrome (ARDS) is a life-threatening, rapid-onset lung failure caused by severe inflammation, which fills the air sacs with fluid and restricts oxygen absorption.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/24/3243711/0/en/Edesa-Biotech-Reports-Additional-Positive-Results-from-Phase-3-Paridiprubart-Study.html">reported</a> results from a 278-patient population, including 104 patients requiring invasive mechanical ventilation (IMV) as well as 174 non-IMV patients.Edesa Biotech said that its experimental drug paridiprubart demonstrated statistically significant reduction in 28-day mortality in the full population to 24% from 33%.Further, treatment benefits were consistent across severity groups and in patients with serious comorbidities. Overall rates of adverse events, serious adverse events, infections, and treatment discontinuations were low and similar between the paridiprubart and placebo groups, the company said. &nbsp;<h2 class="st-heading-2">CEO Expresses Optimism</h2>“The consistency of mortality reduction and clinical improvement across all 278 randomized patients, including less severe patients as well as those with ARDS complicated by acute kidney injury, sepsis and pneumonia, underscores the versatility and transformative potential of paridiprubart to address multiple critical unmet medical needs,” said CEO Par Nijhawan.The chief also added that the company is advancing regulatory discussions and evaluating strategic collaborations and partnership opportunities which could potentially accelerate development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EDSA stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user said that they are now waiting for that “first real surge” in stock price.<stembedurl>https://www.stocktwits.com/topstockalerts/message/645761015</stembedurl><a href="https://stocktwits.com/symbol/EDSA">EDSA stock</a> has dropped 29% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ark-cathie-wood-rebuts-citrini-ai-thought-piece/cZRw3pOR4Cp">ARK’s Cathie Wood Rebuts Citrini AI Thought Piece, Predicts Opportunities After Near-Term Disruptions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did EDSA Stock Rally More Than 70% Today?

Edesa Biotech said that data from a late-stage study of its experimental drug for the treatment of Acute Respiratory Distress Syndrome affirmed statistically significant mortality reductions.

Equity

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

EDSA
Edesa Biotech Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest EDSA News

EDSAEdesa Biotech Inc